Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05725018 · ClinicalTrials.gov registry record · Phase 3
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
A Phase 3 study of Epidermolysis Bullosa and Recessive Dystrophic Epidermolysis Bullosa, sponsored by Abeona Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT05725018 is a Phase 3 study of Epidermolysis Bullosa and Recessive Dystrophic Epidermolysis Bullosa that is active but no longer recruiting, run by Abeona Therapeutics. The registered enrollment target is 12 participants, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (37% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05725018, a Phase 3 study of Epidermolysis Bullosa and Recessive Dystrophic Epidermolysis Bullosa, is active but no longer recruiting, sponsored by Abeona Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen \[C7\] expression) for the treatment of large, chronic DEB wounds in new and previously EB-101 treated patients 12 months and older.
Conditions Studied
Interventions
- BIOLOGICAL EB-101 Surgical application of RDEB wounds
Study Locations (2)
California
- Stanford University - Redwood City
Massachusetts
- University of Massachusetts Medical School - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-04-02 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05725018
The ClinicalTrials.gov registry entry for NCT05725018 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 19-participant average among 10 other Epidermolysis Bullosa trials with a reported enrollment target (37% lower). The listed sponsor is Abeona Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Epidermolysis Bullosa appearing as the primary indexed condition, and to 1 intervention - of which EB-101 Surgical application of RDEB wounds is the first listed.
NCT05725018 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05725018 about?
NCT05725018 is a clinical study titled "A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients". To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen \[C7\] expression) for the treatment of large, chronic DEB wounds in new and previously EB-101 treated patients 12 months and older.
What is the current status of trial NCT05725018?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 12 participants. The study started on 2023-04-02. Estimated completion is 2025-09-30.
What conditions does trial NCT05725018 study?
This clinical trial studies the following conditions: Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, RDEB.
What interventions are being tested in trial NCT05725018?
The interventions under investigation include: EB-101 Surgical application of RDEB wounds (BIOLOGICAL).
Who is sponsoring clinical trial NCT05725018?
This trial is sponsored by Abeona Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05725018 being conducted?
This trial has 2 study locations across California, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
ACTIVE NOT RECRUITING · Phase 3
-
Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
COMPLETED · Phase 3
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution
COMPLETED · Early Phase 1
-
Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa
COMPLETED · Phase 2
-
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
COMPLETED · Phase 2
Explore more on PlainTrial
Epidermolysis Bullosa
All registered trials for this condition
Recessive Dystrophic Epidermolysis Bullosa
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.